Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) is committed to strive toward better health for patients through leading innovation in medicine. It is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company and one with a 230-year heritage. Takeda's U.S. clinical development activities are conducted via Takeda Global Research & Development Center, Inc. (TGRD).
The respective companies currently market oral diabetes, insomnia, rheumatology, gastroenterology, and cardiovascular treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic, gastroenterology, neurology and other conditions.
Our mission is simple and compelling: we are committed to strive toward better health for patients worldwide through leading innovation in medicine. Our commitment to patients, employees, partners, and the larger community gives us the purpose to build on the tremendous success we enjoy as an emerging global leader in the pharmaceutical industry.
This mission:
- • Drives our research and development of prescription drugs
- • Promotes our commitment to social responsibility
- • Marks our growth and success
Our History
Over two centuries ago, a small medicine shop was opened in Doshomachi, Osaka, Japan to provide medicines to local merchants and doctors. This was the beginning of the present-day Takeda family of pharmaceutical companies. Many generations later, in 1998, Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) was introduced.
In 1999, the U.S. Food and Drug Administration (FDA) approved ACTOS® (pioglitazone HCl) for marketing in the United States. The success of ACTOS was a catalyst for the growth we continue to achieve. TPUSA began with three employees in 1998; we now have more than 2,800 employees.
Takeda Global Research & Development was established in 2004 and its 600 employees are responsible for Takeda's clinical research and development in the U.S. and for supporting clinical and product development activity for TPUSA. With a robust pipeline of compounds in development for diabetes, cardiovascular disease and other conditions, Takeda rapidly brings innovative products to market to improve patient health and enhance the practice of medicine.
In 2008, Takeda and Abbott evenly divided their joint venture—TAP Pharmaceutical Products Inc—and the subsequent integration with two of Takeda’s wholly owned U.S. subsidiaries, TPUSA and TGRD, created one of the top 15 pharmaceutical companies in the United States.
To find out more about Takeda's global operations, please visit http://www.takeda.com 
.